Abstract
This is a report of a case with mucous membrane pemphigoid (MMP) with severe eye involvement and concurrent COVID-19 treated successfully using simultaneous high dose intravenous immunoglobulin (IVIg) and anti-viral treatment as hydroxychloroquine, lopinavir/ritonavir, and ribavirin. He had finished a 2-g cycle of rituximab (RTX) in late January. He was receiving mycophenolate mofetil (MMF) for one month and 30 mg prednisolone for three months until his hospitalization. Prednisolone was tapered to 15 mg when current COVID-19 was suspected, considering his recent cough, dyspnea, and fever.
Keywords:
COVID-19; IVIg; Mucous membrane pemphigoid.
MeSH terms
-
Adult
-
Anti-Bacterial Agents / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Betacoronavirus
-
COVID-19
-
COVID-19 Drug Treatment
-
Coronavirus Infections / complications
-
Coronavirus Infections / diagnostic imaging
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / therapy*
-
Deprescriptions
-
Diabetes Mellitus, Type 2 / complications
-
Drug Combinations
-
Drug Therapy, Combination
-
Humans
-
Hypertension / complications
-
Immunoglobulins, Intravenous / therapeutic use*
-
Immunologic Factors / therapeutic use*
-
Iran
-
Lopinavir / therapeutic use
-
Male
-
Mycophenolic Acid / therapeutic use
-
Oseltamivir / therapeutic use
-
Pandemics
-
Pemphigoid, Benign Mucous Membrane / complications
-
Pemphigoid, Benign Mucous Membrane / therapy*
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / diagnostic imaging
-
Pneumonia, Viral / therapy*
-
Prednisolone / therapeutic use
-
Ritonavir / therapeutic use
-
Rituximab / therapeutic use
-
SARS-CoV-2
-
Tomography, Spiral Computed
Substances
-
Anti-Bacterial Agents
-
Antiviral Agents
-
Drug Combinations
-
Immunoglobulins, Intravenous
-
Immunologic Factors
-
lopinavir-ritonavir drug combination
-
Oseltamivir
-
Lopinavir
-
Rituximab
-
Prednisolone
-
Mycophenolic Acid
-
Ritonavir